Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Completed

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL and will predict CLL patients that have a more aggressive form of the disease. The investigators work will also provide direct evidence that LPL is expressed on CLL cells and provides a critical source of fatty acids required by the CLL cells to grow and survive. Fatty acid metabolism may become a therapeutic target in CLL in the future.

Key facts

Study ID

NCT01460238

Run by

Dartmouth-Hitchcock Medical Center

People needed

29

Starts

2011-10-01

Expected to finish

2018-05-01

Last updated by the study team

2019-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
• Patients undergoing routine blood draws as part of their ongoing follow up for CLL
• 18 years or older
• Ability to provide consent in English
• Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.

You may not qualify if…

• Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
• other hematologic malignancy or other disease process within the past 6 months are excluded.

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.